Insider Selling: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider Sells 5,000 Shares of Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) insider William Ho sold 5,000 shares of RAPT Therapeutics stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $25.56, for a total value of $127,800.00. Following the completion of the transaction, the insider now directly owns 35,072 shares of the company’s stock, valued at $896,440.32. The sale was disclosed in a legal filing with the SEC, which is available through this link.

William Ho also recently made the following trade(s):

• On Thursday, December 29th, William Ho sold 5,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $18.03, for a total value of $90,150.00.
• On Monday, November 28th, William Ho sold 5,000 shares of RAPT Therapeutics stock. The stock was sold at an average price of $17.87, for a total value of $89,350.00.
• On Wednesday, November 2nd, William Ho sold 5,000 shares of RAPT Therapeutics stock. The stock was sold at an average price of $22.32, for a total value of $111,600.00.

RAPT Therapeutics Trading Up 4.5 %

NASDAQ RAPT opened at $28.18 on Monday. The business’s 50-day moving average price is $20.00 and its two-hundred day moving average price is $22.10. RAPT Therapeutics, Inc. has a 12 month low of $9.85 and a 12 month high of $32.45. The firm has a market capitalization of $842.89 million, a PE ratio of -11.05 and a beta of 0.30.

RAPT Therapeutics (NASDAQ:RAPT – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. RAPT Therapeutics had a negative return on equity of 42.28% and a negative net margin of 2,346.32%. As a group, analysts forecast that RAPT Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Candriam S.C.A. boosted its position in shares of RAPT Therapeutics by 67.6% during the 2nd quarter. Candriam S.C.A. now owns 264,385 shares of the company’s stock valued at $4,825,000 after purchasing an additional 106,621 shares in the last quarter. Woodline Partners LP boosted its position in shares of RAPT Therapeutics by 139.6% during the 2nd quarter. Woodline Partners LP now owns 859,008 shares of the company’s stock valued at $15,677,000 after purchasing an additional 500,565 shares in the last quarter. Barclays PLC boosted its position in shares of RAPT Therapeutics by 1,610.7% during the 3rd quarter. Barclays PLC now owns 45,026 shares of the company’s stock valued at $1,084,000 after purchasing an additional 42,394 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of RAPT Therapeutics during the 3rd quarter valued at about $153,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of RAPT Therapeutics during the 3rd quarter valued at about $291,000.

Analyst Upgrades and Downgrades

RAPT has been the subject of a number of research analyst reports. Guggenheim initiated coverage on RAPT Therapeutics in a report on Wednesday, January 4th. They set a “buy” rating and a $55.00 price target for the company. HC Wainwright reduced their price objective on RAPT Therapeutics from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, November 14th. Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 4th. Piper Sandler reduced their price objective on RAPT Therapeutics from $34.00 to $33.00 in a research report on Thursday, December 8th. Finally, The Goldman Sachs Group began coverage on RAPT Therapeutics in a research report on Thursday, December 1st. They set a “buy” rating and a $27.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $44.14.

About RAPT Therapeutics

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.